ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer

Bital Savir-Baruch, Kevin P. Banks, Jonathan E. McConathy, Olga P. Molchanova-Cook, Ephraim E. Parent, Amol Takalkar, Mark Tulchinsky, Jian Q. Yu, Rathan Subramaniam, David M. Schuster

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The American College of Radiology (ACR) and American College of Nuclear Medicine (ACNM) collaborated to develop a clinical practice document for the performance of fluciclovine positron-emission tomography (PET) / computed tomography (CT) in the evaluation of patients with suspected prostate cancer recurrence based on the elevation of prostate-specific antigen (PSA) level (biochemical recurrence) after prior therapy. Prostate cancer is the third leading cause of cancer death in the United States. Up to 50% of patients diagnosed with prostate cancer will develop biochemical failure after initial therapy. The differentiation of local from extraprostatic recurrence plays a critical role in patient management. The use of functional imaging targeting features of cancer metabolism has proven highly useful in this regard. Amino acid transport is upregulated in prostate cancer. Fluciclovine (anti-1-Amino-3-F-18-fluorocyclobutane-1-carboxylic acid, FACBC, Axumin™) is an artificial amino acid PET tracer which demonstrates utility in the diagnosis of recurrent prostate cancer with significant added value to conventional imaging.

Original languageEnglish (US)
Pages (from-to)909-917
Number of pages9
JournalClinical Nuclear Medicine
Volume43
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Fluorine
Nuclear Medicine
Radiology
Prostatic Neoplasms
Recurrence
Amino Acids
Prostate-Specific Antigen
Positron-Emission Tomography
Cause of Death
Neoplasms
Positron Emission Tomography Computed Tomography
Therapeutics

Keywords

  • 18F-fluciclovine
  • amino acid
  • axumin
  • FACBC
  • PET/CT
  • prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Savir-Baruch, B., Banks, K. P., McConathy, J. E., Molchanova-Cook, O. P., Parent, E. E., Takalkar, A., ... Schuster, D. M. (2018). ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. Clinical Nuclear Medicine, 43(12), 909-917. https://doi.org/10.1097/RLU.0000000000002310

ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. / Savir-Baruch, Bital; Banks, Kevin P.; McConathy, Jonathan E.; Molchanova-Cook, Olga P.; Parent, Ephraim E.; Takalkar, Amol; Tulchinsky, Mark; Yu, Jian Q.; Subramaniam, Rathan; Schuster, David M.

In: Clinical Nuclear Medicine, Vol. 43, No. 12, 01.12.2018, p. 909-917.

Research output: Contribution to journalArticle

Savir-Baruch, B, Banks, KP, McConathy, JE, Molchanova-Cook, OP, Parent, EE, Takalkar, A, Tulchinsky, M, Yu, JQ, Subramaniam, R & Schuster, DM 2018, 'ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer', Clinical Nuclear Medicine, vol. 43, no. 12, pp. 909-917. https://doi.org/10.1097/RLU.0000000000002310
Savir-Baruch, Bital ; Banks, Kevin P. ; McConathy, Jonathan E. ; Molchanova-Cook, Olga P. ; Parent, Ephraim E. ; Takalkar, Amol ; Tulchinsky, Mark ; Yu, Jian Q. ; Subramaniam, Rathan ; Schuster, David M. / ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. In: Clinical Nuclear Medicine. 2018 ; Vol. 43, No. 12. pp. 909-917.
@article{7f495e35a10a4b44976f6ac0dd1182c4,
title = "ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer",
abstract = "The American College of Radiology (ACR) and American College of Nuclear Medicine (ACNM) collaborated to develop a clinical practice document for the performance of fluciclovine positron-emission tomography (PET) / computed tomography (CT) in the evaluation of patients with suspected prostate cancer recurrence based on the elevation of prostate-specific antigen (PSA) level (biochemical recurrence) after prior therapy. Prostate cancer is the third leading cause of cancer death in the United States. Up to 50{\%} of patients diagnosed with prostate cancer will develop biochemical failure after initial therapy. The differentiation of local from extraprostatic recurrence plays a critical role in patient management. The use of functional imaging targeting features of cancer metabolism has proven highly useful in this regard. Amino acid transport is upregulated in prostate cancer. Fluciclovine (anti-1-Amino-3-F-18-fluorocyclobutane-1-carboxylic acid, FACBC, Axumin™) is an artificial amino acid PET tracer which demonstrates utility in the diagnosis of recurrent prostate cancer with significant added value to conventional imaging.",
keywords = "18F-fluciclovine, amino acid, axumin, FACBC, PET/CT, prostate cancer",
author = "Bital Savir-Baruch and Banks, {Kevin P.} and McConathy, {Jonathan E.} and Molchanova-Cook, {Olga P.} and Parent, {Ephraim E.} and Amol Takalkar and Mark Tulchinsky and Yu, {Jian Q.} and Rathan Subramaniam and Schuster, {David M.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/RLU.0000000000002310",
language = "English (US)",
volume = "43",
pages = "909--917",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer

AU - Savir-Baruch, Bital

AU - Banks, Kevin P.

AU - McConathy, Jonathan E.

AU - Molchanova-Cook, Olga P.

AU - Parent, Ephraim E.

AU - Takalkar, Amol

AU - Tulchinsky, Mark

AU - Yu, Jian Q.

AU - Subramaniam, Rathan

AU - Schuster, David M.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The American College of Radiology (ACR) and American College of Nuclear Medicine (ACNM) collaborated to develop a clinical practice document for the performance of fluciclovine positron-emission tomography (PET) / computed tomography (CT) in the evaluation of patients with suspected prostate cancer recurrence based on the elevation of prostate-specific antigen (PSA) level (biochemical recurrence) after prior therapy. Prostate cancer is the third leading cause of cancer death in the United States. Up to 50% of patients diagnosed with prostate cancer will develop biochemical failure after initial therapy. The differentiation of local from extraprostatic recurrence plays a critical role in patient management. The use of functional imaging targeting features of cancer metabolism has proven highly useful in this regard. Amino acid transport is upregulated in prostate cancer. Fluciclovine (anti-1-Amino-3-F-18-fluorocyclobutane-1-carboxylic acid, FACBC, Axumin™) is an artificial amino acid PET tracer which demonstrates utility in the diagnosis of recurrent prostate cancer with significant added value to conventional imaging.

AB - The American College of Radiology (ACR) and American College of Nuclear Medicine (ACNM) collaborated to develop a clinical practice document for the performance of fluciclovine positron-emission tomography (PET) / computed tomography (CT) in the evaluation of patients with suspected prostate cancer recurrence based on the elevation of prostate-specific antigen (PSA) level (biochemical recurrence) after prior therapy. Prostate cancer is the third leading cause of cancer death in the United States. Up to 50% of patients diagnosed with prostate cancer will develop biochemical failure after initial therapy. The differentiation of local from extraprostatic recurrence plays a critical role in patient management. The use of functional imaging targeting features of cancer metabolism has proven highly useful in this regard. Amino acid transport is upregulated in prostate cancer. Fluciclovine (anti-1-Amino-3-F-18-fluorocyclobutane-1-carboxylic acid, FACBC, Axumin™) is an artificial amino acid PET tracer which demonstrates utility in the diagnosis of recurrent prostate cancer with significant added value to conventional imaging.

KW - 18F-fluciclovine

KW - amino acid

KW - axumin

KW - FACBC

KW - PET/CT

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85056266598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056266598&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002310

DO - 10.1097/RLU.0000000000002310

M3 - Article

VL - 43

SP - 909

EP - 917

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 12

ER -